News and Trends 5 Oct 2022
Intravacc to develop intranasal gonorrhea vaccine with $14.6M NIH/NIAID contract
Intravacc has been awarded a contract with base and options that may total US$14.6 million for the development of a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). The contract has been awarded by the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), Gonorrhea is a sexually […]